ArticleBiomaterials2012
Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs.
Article in Biomaterials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 218 citations in OpenAlex.
- Application of chitosan-based nanogels for dermal and transdermal delivery systems.Journal of materials science. Materials in medicine · 2025Review
- Engineered Sulfonated Bacterial Cellulose Hydrogel with Dual Bioactive-Drug Delivery Functions for Precision Treatment of Psoriasis.Biomacromolecules · 2025Article
- Polymeric nanocarriers in drug delivery, bioimaging, and biosensing: advances and perspectives on nanomicelles, nanogels, and dendrimers.RSC advances · 2025Review
- Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective.Drug delivery and translational research · 2025Review
- Advanced Immunomodulatory Biomaterials for Therapeutic Applications.Advanced healthcare materials · 2025Review
- Nanogels as Drug Delivery Carrier: A Narrative Review on Formulation Techniques, Characterization, Applications and Patents.Current pharmaceutical biotechnology · 2025Review
- Follicular mediated etodolac phosalosomal gel for contact dermatitis alleviation, insights from optimization to in-vivo appraisal.Scientific reports · 2024Article
- Polymeric Nanohydrogel in Topical Drug Delivery System.International journal of nanomedicine · 2024Review
- Secondary metabolites in topical infectious diseases and nanomedicine applications.Nanomedicine (London, England) · 2024Review
- Mucoadhesive, Fluconazole-Loaded Nanogels Complexed with Sulfhydryl-β-cyclodextrin for Oral Thrush Treatment.AAPS PharmSciTech · 2023Article
- Co-Encapsulation of Drugs for Topical Application-A Review.Molecules (Basel, Switzerland) · 2023Review
- Nanogels as novel drug nanocarriers for CNS drug delivery.Frontiers in molecular biosciences · 2023Review
- Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope.Journal of functional biomaterials · 2022Review
- Development and Characterization of Cyclodextrin-Based Nanogels as a New Ibuprofen Cutaneous Delivery System.Pharmaceutics · 2022Article
- Natural polysaccharide-based biodegradable polymeric platforms for transdermal drug delivery system: a critical analysis.Drug delivery and translational research · 2022Review
- Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies.Journal of nanobiotechnology · 2022Review
- Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy.Postepy dermatologii i alergologii · 2022Review
- A multifunctional composite hydrogel as an intrinsic and extrinsic coregulator for enhanced therapeutic efficacy for psoriasis.Journal of nanobiotechnology · 2022Article
- Nanocarriers for Skin Applications: Where Do We Stand?Angewandte Chemie (International ed. in English) · 2022Review
- Synthesis and Evaluation of Finasteride-Loaded HPMC-Based Nanogels for Transdermal Delivery: A Versatile Nanoscopic Platform.BioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The aim of this study was to develop an effective drug delivery system for the simultaneous topical delivery of two anti-inflammatory drugs, spantide II (SP) and ketoprofen (KP). To achieve this primary goal, we have developed a skin permeating nanogel system (SPN) containing surface modified polymeric bilayered nanoparticles along with a gelling agent. Poly-(lactide-co-glycolic acid) and chitosan were used to prepare bilayered nanoparticles (NPS) and the surface was modified with oleic acid (NPSO). Hydroxypropyl methyl cellulose (HPMC) and Carbopol with the desired viscosity were utilized to prepare the nanogels. The nanogel system was further investigated for in vitro skin permeation, drug release and stability studies. Allergic contact dermatitis (ACD) and psoriatic plaque like model were used to assess the effectiveness of SPN. Dispersion of NPSO in HPMC (SPN) produced a stable and uniform dispersion. In vitro permeation studies revealed increase in deposition of SP for the SP-SPN or SP+KP-SPN in the epidermis and dermis by 8.5 and 9.5 folds, respectively than SP-gel. Further, the deposition of KP for KP-SPN or SP+KP-SPN in epidermis and dermis was 9.75 and 11.55 folds higher, respectively than KP-gel. Similarly the amount of KP permeated for KP-SPN or SP+KP-SPN was increased by 9.92 folds than KP-gel. The ear thickness in ACD model and the expression of IL-17 and IL-23; PASI score and TEWL values in psoriatic plaque like model were significantly less (p < 0.001) for SPN compared to control gel. Our results suggest that SP+KP-SPN have significant potential for the percutaneous delivery of SP and KP to the deeper skin layers for treatment of various skin inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.